Format

Send to

Choose Destination
Pediatr Infect Dis J. 2015 Oct;34(10):e260-3. doi: 10.1097/INF.0000000000000818.

Pneumococcal Meningitis Vaccine Breakthroughs and Failures After Routine 7-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Children in France.

Author information

1
From the *Groupe de Pathologie Infectieuse Pédiatrique (GPIP) de la Société Française de Pédiatrie (SFP), Paris, France; †Service de pédiatrie générale, Centre Hospitalier Intercommunal de Créteil, Créteil, France; ‡Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Saint-Maur-des-Fossés, France; §Centre de Recherche Clinique (CRC), Centre Hospitalier Intercommunal de Créteil, Créteil, France; ¶Centre National de Référence des pneumocoques, hôpital européen Georges-Pompidou, Paris, France; ‖Centre d'étude des déficits immunitaires (CEDI), hôpital Necker-Enfants Malades, Paris, France; **Laboratoire de Génétique Humaine des Maladies Infectieuses, INSERM UMR 1163-Institut Imagine, Université Paris Descartes-Sorbonne Paris Cité, Paris, France; and ††Service de néonatologie, unité court séjour petits nourrissons, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Abstract

We collected cases of pneumococcal meningitis vaccine breakthrough (VBT) and vaccine failure (VF) from 2003 to 2013 after the implementation of pneumococcal conjugate vaccines (PCVs) in France. VBT accounted for 3.2% of the cases (PCV7 era: 24 of 943, PCV13 era: 15 of 290) and VF 0.6% (PCV7 era: 6 of 943, PCV13 era: 2 of 290). VBT and VF are rare and occur in most cases in children younger than 2 years. The serotype 19F was the most frequent cause even after the introduction of PCV13.

PMID:
26181894
DOI:
10.1097/INF.0000000000000818
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center